Key result
Calcium antagonists preserved or improved renal function in short-term studies, but long-term clinical trials are required to confirm sustained protection.
Why the study?
Do calcium antagonists protect the human kidney from systemic and glomerular hypertension in patients with essential hypertension and advanced renal parenchymal disease?
Population
Patients with essential hypertension and hypertension associated with advanced renal parenchymal disease
Design
Review
Authors
Loading...
Short-term renal preservation data should not alter prescribing; leaves open whether calcium antagonists confer sustained renoprotection in essential hypertension.
Do calcium antagonists protect the human kidney from systemic and glomerular hypertension in patients with essential hypertension and advanced renal parenchymal disease?
Short-term data suggest calcium antagonists may preserve renal function in hypertensive patients, but long-term clinical trials are necessary to confirm renoprotective effects.
Bauer et al. (1989) conducted a review in Essential hypertension and hypertension associated with advanced renal parenchymal disease. Calcium antagonists (amlodipine, diltiazem, nifedipine) was evaluated on Renal function (glomerular filtration, effective renal plasma flow, urinary protein excretion). Calcium antagonists preserved or improved renal function in short-term studies, but long-term clinical trials are required to confirm sustained protection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: